ChromaDex Co. (NASDAQ:CDXC – Get Free Report) saw a large decline in short interest in September. As of September 15th, there was short interest totalling 2,950,000 shares, a decline of 5.4% from the August 31st total of 3,120,000 shares. Approximately 6.2% of the shares of the stock are short sold. Based on an average trading volume of 387,800 shares, the days-to-cover ratio is presently 7.6 days.
Analysts Set New Price Targets
A number of equities research analysts have commented on the company. Roth Mkm reissued a “buy” rating and issued a $6.00 target price on shares of ChromaDex in a report on Wednesday, June 12th. HC Wainwright reiterated a “buy” rating and issued a $6.00 price target on shares of ChromaDex in a report on Friday, August 9th.
Check Out Our Latest Stock Report on ChromaDex
Insider Buying and Selling
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently modified their holdings of the company. WINTON GROUP Ltd acquired a new stake in ChromaDex during the second quarter worth approximately $597,000. Bank of New York Mellon Corp boosted its stake in ChromaDex by 170.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 190,442 shares of the company’s stock valued at $520,000 after purchasing an additional 119,915 shares during the last quarter. Rhumbline Advisers purchased a new position in shares of ChromaDex in the 2nd quarter worth approximately $124,000. Perritt Capital Management Inc. bought a new stake in shares of ChromaDex in the 1st quarter worth approximately $139,000. Finally, Renaissance Technologies LLC raised its holdings in ChromaDex by 8.4% during the 2nd quarter. Renaissance Technologies LLC now owns 416,100 shares of the company’s stock valued at $1,136,000 after acquiring an additional 32,400 shares during the period. 15.41% of the stock is owned by institutional investors and hedge funds.
ChromaDex Stock Down 3.9 %
CDXC traded down $0.15 during trading on Monday, hitting $3.65. The company’s stock had a trading volume of 343,618 shares, compared to its average volume of 304,019. The stock has a market capitalization of $275.72 million, a price-to-earnings ratio of -73.00 and a beta of 1.86. ChromaDex has a 12 month low of $1.25 and a 12 month high of $4.65. The firm’s 50 day moving average price is $3.27 and its two-hundred day moving average price is $3.23.
About ChromaDex
ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.
Featured Stories
- Five stocks we like better than ChromaDex
- Low PE Growth Stocks: Unlocking Investment Opportunities
- TJX Stock: A Buying Opportunity Before the Holiday Rush
- Stock Splits, Do They Really Impact Investors?
- Micron’s Blowout Results Pave the Way for Seagate’s Stock Surge
- What is a Bond Market Holiday? How to Invest and Trade
- Zeta Global’s AI Cloud: Your Secret Weapon for Massive Growth
Receive News & Ratings for ChromaDex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChromaDex and related companies with MarketBeat.com's FREE daily email newsletter.